David Malcom Rodman - 13 Jan 2025 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Chief Medical Officer
Signature
/s/ Adam Levy, Attorney-in-fact
Issuer symbol
MLYS
Transactions as of
13 Jan 2025
Net transactions value
+$9,567
Form type
4
Filing time
15 Jan 2025, 21:45:31 UTC
Previous filing
13 Dec 2024
Next filing
13 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLYS Common Stock Options Exercise $2,710 +5,018 +3.4% $0.5400 151,823 13 Jan 2025 Direct F1
transaction MLYS Common Stock Options Exercise $6,857 +6,349 +4.2% $1.08 158,172 13 Jan 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Stock Option Options Exercise $0 -5,018 -100% $0.000000 0 13 Jan 2025 Common Stock 5,018 $0.5400 Direct F2
transaction MLYS Stock Option Options Exercise $0 -6,349 -4.7% $0.000000 128,577 13 Jan 2025 Common Stock 6,349 $1.08 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This balance includes 797 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported.
F2 The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.
F3 The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.